AARTIDRUGS vs CIPLA: Stock Comparison

Aarti Drugs Limited vs Cipla Ltd

Live data: 22 July 2026, 2:39 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Aarti Drugs Limited shows a lower P/E, a higher ROE and faster revenue growth, while Cipla Ltd shows a higher dividend yield, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarti Drugs Limited and Cipla Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AARTIDRUGS is more favourable on 7 of 13 scored metrics and CIPLA on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹3,760 Cr
P/E Ratio
AARTIDRUGS has a lower P/E
20.04x vs 29.83x
P/B Ratio
AARTIDRUGS has a lower P/B
2.52x vs 3.36x
EPS
CIPLA has higher earnings per share
₹48.01 vs ₹21.81
Dividend Yield
CIPLA has a higher dividend yield
0.9% vs 0.48%
Revenue Growth (TTM YoY)
AARTIDRUGS has faster revenue growth
6.4% vs -2.1%
EPS Growth (TTM YoY)
AARTIDRUGS has faster EPS growth
-12% vs -54.6%
Qtr Sales Growth
AARTIDRUGS has stronger quarterly sales growth
6.43% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSCIPLA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSCIPLA
Live Price₹413.4₹1,412.3
Day Change-3.16%-1.41%
Volume2.79 L12.96 L
52-Week High₹551.75₹1,673
52-Week Low₹318.95₹1,165.7
Distance from 52W High-25.07%-15.58%

Valuation

MetricAARTIDRUGSCIPLA
Market Cap₹3,760 Cr₹1.14 L Cr
P/E Ratio20.04x29.83x
P/B Ratio2.52x3.36x
EPS₹21.81₹48.01
Book Value₹169.79₹426.25
Dividend Yield0.48%0.9%

Growth

MetricAARTIDRUGSCIPLA
Revenue Growth (TTM YoY)6.4%-2.1%
EPS Growth (TTM YoY)-12%-54.6%
Qtr Sales Growth6.43%-2.8%
Qtr Profit Growth-12.2%-54.6%

Profitability & Leverage

MetricAARTIDRUGSCIPLA
ROE13.4%11.6%
ROCE11.9%15.5%
Net Margin7.6%13.96%
Operating Margin12%20.9%
Debt to Equity0.37x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAARTIDRUGSCIPLA
Promoter Holding55.03%9.17%
FII Holding1.58% 0.57 pp22.56% 1.37 pp
DII Holding10.22% 0.1 pp31.97% 1.25 pp
Public Holding33.18% 0.48 pp16.25% 0.12 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarti Drugs Limited and Cipla Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.